

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 September 2024 (12.09.2024)



(10) International Publication Number
WO 2024/184305 A1

(51) International Patent Classification:

C07D 233/64 (2006.01) A61K 31/4178 (2006.01)
C07D 493/08 (2006.01) A61K 31/4164 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/EP2024/055581

(22) International Filing Date:

04 March 2024 (04.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23382194.1 03 March 2023 (03.03.2023) EP

(71) Applicants: **UNIVERSITAT DE BARCELONA** [ES/ES]; Centre de Patents de la UB, Baldiri Reixac, 4 - Torre D, 08028 Barcelona (ES). **QPS CLINICAL SERVICES GMBH** [AT/AT]; Parkring 12, 8074 Grambach (AT).

(72) Inventors: **MUÑOZ-TORRERO LÓPEZ-IBARRA, Diego**; UNIVERSITAT DE BARCELONA, Centre de Patents de la UB, Baldiri Reixac, 4 - Torre D, 08028 Barcelona (ES). **VÁZQUEZ CRUZ, Santiago**; UNIVERSITAT DE BARCELONA, Centre de Patents de la UB, Baldiri Reixac, 4 - Torre D, 08028 Barcelona (ES). **MARTÍNEZ CONDE, Noemí**; UNIVERSITAT DE BARCELONA, Centre de Patents de la UB, Baldiri Reixac, 4 - Torre D, 08028 Barcelona (ES). **PUJOL BECH, Eugènia-Alexandra**; UNIVERSITAT DE BARCELONA, Centre de Patents de la UB, Baldiri Reixac, 4 - Torre D, 08028 Barcelona (ES). **LÖFFLER, Tina**; QPS Clinical Services GmbH, Parkring 12, 8074 Grambach (AT). **BRUNNER, Daniela**; QPS Clinical Services GmbH, Parkring 12, 8074 Grambach (AT). **PROKESCH, Manuela**; QPS Clinical Services GmbH, Parkring 12, 8074 Grambach (AT). **RABL, Roland**; QPS Clinical Services GmbH, Parkring 12, 8074 Grambach (AT). **HUTTER-PAIER, Birgit**; QPS Clinical Services GmbH, Parkring 12, 8074 Grambach (AT).

(74) Agent: **HOFFMANN EITLE S.L.U.**; Paseo de la Castellana 140, 3ª Planta, Edificio Lima, 28046 Madrid (ES).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE



(57) Abstract: Compounds (I) are provided, where R^1 and R^2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula $-(CH_2)_n-$ with $n = 0, 1$ or 2 , or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.

WO 2024/184305 A1